Hypopharyngeal cancer
Drug research and approvals for hypopharyngeal cancer: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 59 studies of hypopharyngeal cancer are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 59
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- TMV Vaccine Alone or With Toripalimab-tpzi for Recurrent Head and Neck Squamous Cell CarcinomaNCT07898124 · Phase 1 · Metaclipse Therapeutics Corporation · starts Oct 1, 2026
- Intraoperative Methadone for the Management of Postoperative Pain in Patients With Head and Neck CancersNCT07857655 · Phase 4 · OHSU Knight Cancer Institute · starts Sep 22, 2026
- A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing…NCT07807163 · Phase 2 · Bicara Therapeutics · starts Sep 1, 2026
- Scheduled IV Fluids in the Supportive Management of Patients Undergoing Chemo-radiotherapy for Head and Neck CancerNCT07784855 · Not applicable · West Virginia University · starts Nov 1, 2026
- Thermotherapy for Head and Neck Cancer PatientsNCT07690618 · Phase 1 · Erasmus Medical Center · starts Sep 1, 2026
- Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and…NCT07667400 · Phase 1 / Phase 2 · National Cancer Institute (NCI) · starts Nov 25, 2026
- Neoadjuvant EGFR-ADC Combined With Anti-PD-1 Monoclonal Antibody in Resectable Locally Advanced Hypopharyngeal Squamous…NCT07665190 · Phase 2 · Tianjin Medical University Cancer Institute and Hospital · starts Jul 1, 2026
- A Machine Learning-Based Risk Prediction Model for Head and Neck Cancerous LesionsNCT07532538 · Not reported · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · starts Apr 30, 2026
- Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Advanced Head and Neck Cancer Who…NCT07441681 · Phase 3 · NRG Oncology · starts Jul 31, 2026
Phase 3 4
- CisplatinDNA inhibitor
- DocetaxelTubulin inhibitor
- FluorouracilThymidylate synthase inhibitor
- Platinum
Phase 2 11
- CetuximabEpidermal growth factor receptor erbB1 inhibitor
- CapecitabineThymidylate synthase inhibitor
- PaclitaxelTubulin inhibitor
- CamrelizumabProgrammed cell death protein 1 antagonist
- IxabepiloneTubulin inhibitor
- LapatinibReceptor protein-tyrosine kinase erbB-2 inhibitor
- SunitinibMacrophage colony stimulating factor receptor inhibitor
- SorafenibSerine/threonine-protein kinase RAF inhibitor
- NimotuzumabEpidermal growth factor receptor erbB1 inhibitor
- ToripalimabProgrammed cell death protein 1 antagonist
- Nedaplatin
Phase 1 or earlier 5
- CarboplatinDNA inhibitor
- IrinotecanDNA topoisomerase I inhibitor
- VorinostatHistone deacetylase 1 inhibitor
- UCN-01Cyclin-dependent kinase 2 inhibitor
- MotolimodToll-like receptor 8 agonist
How its trials ended
37 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 5 whose ending is known, 40% met their primary endpoint, 0% missed it and 60% stopped early.
- Completed, result not reported1232%
- Ongoing1232%
- Status unknown822%
- Met its primary endpoint25%
- Stopped: enrollment or feasibility25%
- Stopped: other or unclear13%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA